Established by the end of 2000, ERIOCHEM is an Argentine pharmaceutical company which specializes in the synthesis of active pharmaceutical ingredients, in the manufacturing of finished pharmaceutical products and the development of added value generics or supergenerics.
Their highly qualified R&D team its devoted to the development of manufacturing processes of sustained release products, the production of active pharmaceutical ingredients, and oncological generics and supergenerics development. Focused on pharmaceutical “sustained release products” based on biodegradable polymers and innovative high tech processes for the production of micro-spheres, ERIOCHEM uses its own techniques in the manufacturing processes of these products.
Contact info:
Mailing Address
Ruta 12 Km 452
3107 Colonia Avellaneda
Entre Ríos
Argentina
Phone
Tel: +54 343 4979125
Fax: ++54 343 4979136
E-Mail
Info@erio.com.ar
The founder of Eriochem discusses his firm’s ambitious technology based on a competitive IP strategy and its exciting research on a radically new oncology platform. Today, Eriochem is a vertically…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
Axios International has been designing and implementing access to healthcare solutions in collaboration with the pharmaceutical industry and other healthcare players across Latin America (LatAm), Europe, the Middle East, Africa,…
Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company’s significant presence in the cluster, its double digit growth…
Florencia Davel, head of LatAm operations for Bristol Myers Squibb (BMS) looks back on a successful four years in position, shaping the regional organisation into a true biopharma player in…
The Head of Viatris Latin America, Patrick Doyle, spoke to PharmaBoardroom about setting up the two-year old company’s Latam affiliate during the pandemic, the decision to focus on specific therapeutic…
Boehringer Ingelheim’s managing director for South America, Dirk van Niekerk, provides an overview of the healthcare climate in South America, the challenges tied to political and economic instability, future opportunities…
Dr Guillermo Chantada, incoming president-elect of the International Society of Paediatric Oncology (SIOP) highlights the progress of paediatric oncology in Latin America and gives a call to arms to the…
PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of…
See our Cookie Privacy Policy Here